PhaseBio Pharmaceuticals Inc (PHAS) stock is lower by -98.02% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives PHAS stock a score of 34 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 0. PHAS's rank also includes a short-term technical score of 5. PHAS has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on PHAS!